Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RA-BE-LEAVE: De-escalation of methotrexate and/or baricitinib in rheumatoid arthritis remission or low disease activity
jRCTs051220168Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of baricitinib and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Started Mar 2023; status: active, not recruiting.
02
Drugs
baricitinibmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs051220168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220168.